

CORRECTION

Open Access



Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

Lorenzo Castagnoli¹, Alma Franceschini¹, Valeria Cancila², Matteo Dugo³, Martina Bigliardi¹, Claudia Chiodoni⁴, Paolo Toneguzzo¹, Viola Regondi¹, Paola A. Corsetto⁵, Filippo Pietrantonio⁶, Serena Mazzucchelli⁷, Fabio Corsi⁸, Antonino Belfiore⁹, Andrea Vingiani^{9,10}, Giancarlo Pruner^{9,10}, Francesca Ligorio^{6,11}, Mario P. Colombo⁴, Elda Tagliabue¹, Claudio Tripodo^{2,11}, Claudio Vernieri^{6,11}, Tiziana Triulzi¹ and Serenella M. Pupa^{1*}

Correction: *J Exp Clin Cancer Res* 44, 19 (2025)
<https://doi.org/10.1186/s13046-025-03276-z>

Following the publication of the original article [1], the authors identified an errors in the author names of Antonino Belfiore and Andrea Vingiani. The correct names are presented below:

The incorrect author name is: Antonio Belfiore
The correct author name is: Antonino Belfiore

The incorrect author name is: Antonio Vingiani
The correct author name is: Andrea Vingiani

The original article can be found online at <https://doi.org/10.1186/s13046-025-03276-z>.

*Correspondence:

Serenella M. Pupa

Serenella.Pupa@istitutotumori.mi.it

¹ Microenvironment and Biomarkers of Solid Tumors Unit, Department of Experimental Oncology, Amadeolab Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy

² Tumor Immunology Unit, Department PROMISE, Universita' Di Palermo, Palermo, Italy

³ Breast Cancer Unit Clinical Translational and Immunotherapy Research, Department of Medical Oncology, IRCCS Ospedale San Rafaële, Milan, Italy

⁴ Molecular Immunology Unit, Department of Experimental Oncology, Amadeolab Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy

⁵ Department of Pharmacologicaland, Biomolecular Sciences "Rodolfo Paoletti", Università Di Milano, Milan, Italy

The author group has been updated above and the original article [1] has been corrected.

Published online: 30 May 2025

Reference

1. Castagnoli L, Franceschini A, Cancila V, et al. CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer. *J Exp Clin Cancer Res*. 2025;44:19. <https://doi.org/10.1186/s13046-025-03276-z>.

⁶ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy

⁷ Department of Biomedical and Clinical Sciences, Università Di Milano, Milan, Italy

⁸ Surgery Department, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy

⁹ Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy

¹⁰ Department of Oncology and Hemato-Oncology, Universita' Di Milano, Milan, Italy

¹¹ IFOM ETS, The AIRC Institute of Molecular Oncology, Milan, Italy

